Higher transcription alleles of the MAOA-uVNTR polymorphism are associated with higher seizure frequency in temporal lobe epilepsy
Carregando...
Citações na Scopus
4
Tipo de produção
article
Data de publicação
2019
Título da Revista
ISSN da Revista
Título do Volume
Editora
ELSEVIER SCIENCE BV
Autores
SANTOS, Bernardo dos
LINDEN, Helio van der
ARRUDA, Francisco
Citação
EPILEPSY RESEARCH, v.149, p.26-29, 2019
Resumo
Background: There is evidence of an imbalance in the neuromodulatory system mediated by serotonin (5-HT) in patients with drug-resistant temporal lobe epilepsy (TLE). This study analyzed the monoamine oxidase A promoter variable number of tandem repeats (MAOA-uVNTR) polymorphism in patients with temporal lobe epilepsy with hippocampal sclerosis (TLE-HS). Therefore, we assessed the association between this genetic variant and seizure predisposition and severity in patients with TLE-HS. Methods: One hundred nineteen patients with TLE-HS and 113 healthy volunteers were assessed. First, we genotyped all individuals for the MAOA-uVNTR genetic polymorphism. Second, we compared patients and controls and evaluated clinical variants of epilepsy. Results: There was no difference between the TLE-HS and control groups regarding genotypic and allelic distributions of MAOA-uVNTR polymorphism (p = 1.000). Higher transcription alleles of the MAOA-uVNTR were associated with higher seizure frequency (p = 0.032) and bilateral tonic-clonic seizures (p = 0.016). Conclusions: In a selected group of patients with TLE-HS, the polymorphism MAOA-uVNTR was associated with some aspects of epilepsy severity, namely seizure frequency and bilateral tonic-clonic seizures.
Palavras-chave
Temporal lobe epilepsy, Serotonin, Monoamine oxidase
Referências
- Alcantara JA, 2018, EUR J NEUROL, V25, P895, DOI 10.1111/ene.13631
- Alcantara JA, 2018, SEIZURE-EUR J EPILEP, V60, P159, DOI 10.1016/j.seizure.2018.07.004
- Bagdy G, 2007, J NEUROCHEM, V100, P857, DOI 10.1111/j.1471-4159.2006.04277.x
- Bouilleret V, 2008, NEUROLOGY, V70, P177, DOI 10.1212/01.wnl.0000297514.47695.48
- BRIERE R, 1986, ANN NEUROL, V19, P26, DOI 10.1002/ana.410190106
- Coan AC, 2013, EXPERT REV NEUROTHER, V13, P1383, DOI 10.1586/14737175.2013.857604
- da Fonseca NC, 2015, EPILEPSY RES, V111, P18, DOI 10.1016/j.eplepsyres.2014.12.013
- DAILEY JW, 1986, EPILEPSIA, V27, P665, DOI 10.1111/j.1528-1157.1986.tb03593.x
- Engel Jr J., 1997, EPILEPSY COMPREHENSI, P2417
- Ghasemi M, 2018, NEUROPHARMACOLOGY, V137, P297, DOI 10.1016/j.neuropharm.2018.05.015
- Klitten LL, 2011, EUR J HUM GENET, V19, P1, DOI 10.1038/ejhg.2010.149
- LOUW D, 1989, CAN J NEUROL SCI, V16, P394
- Merlet I, 2004, NEUROIMAGE, V22, P886, DOI 10.1016/j.neuroimage.2004.02.014
- MURPHY DL, 1979, NEUROCHEM RES, V4, P53, DOI 10.1007/BF00963831
- NaffahMazzacoratti MG, 1996, EPILEPSY RES, V25, P133, DOI 10.1016/0920-1211(96)00030-7
- Newman TK, 2005, BIOL PSYCHIAT, V57, P167, DOI 10.1016/j.biopsych.2004.10.012
- NICOLETTI F, 1986, J NEUROCHEM, V46, P270, DOI 10.1111/j.1471-4159.1986.tb12957.x
- Paredes VEB, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0141098
- PINTOR M, 1990, SYNAPSE, V5, P152, DOI 10.1002/syn.890050210
- Sabol SZ, 1998, HUM GENET, V103, P273, DOI 10.1007/s004390050816
- Savic I, 2004, NEUROLOGY, V62, P1343, DOI 10.1212/01.WNL.0000123696.98166.AF
- Stefulj J, 2010, NEUROSCI LETT, V478, P29, DOI 10.1016/j.neulet.2010.04.060
- TSUDA H, 1993, NEUROCHEM RES, V18, P111, DOI 10.1007/BF01474672
- Vincentiis S, 2018, EPILEPSY BEHAV, V83, P181, DOI 10.1016/j.yebeh.2018.03.032
- Werhahn KJ, 2006, EPILEPSIA, V47, P1392, DOI 10.1111/j.1528-1167.2006.00561.x
- WESTLUND KN, 1993, BRAIN RES, V612, P221, DOI 10.1016/0006-8993(93)91664-E
- Whibley A, 2010, EUR J HUM GENET, V18, P1095, DOI 10.1038/ejhg.2010.41
- Xiao ZY, 2009, J BIOL CHEM, V284, P10980, DOI 10.1074/jbc.M806760200